Neuroblastoma
484
71
106
241
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
71 trials with published results (15%)
Research Maturity
241 completed trials (50% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.5%
51 terminated out of 484 trials
82.5%
-4.1% vs benchmark
6%
31 trials in Phase 3/4
29%
71 of 241 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 241 completed trials
Clinical Trials (484)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
MCT for the Harvard/UCSF ROBIN Center
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
A Prospective Image Reevaluation Study to Assess the Efficacy of 18F-mFBG PET Imaging in Subjects With Neuroblastoma
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Therapy for Children With Advanced Stage Neuroblastoma
Rapid Administration Pilot for Infusing Dinutuximab
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Biomarkers of Resiliency In Childhood Cancer Surgery
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
B7-H3.CD28Z.CART in Solid Tumors